It's not that Facebook doesn't allow scraping, it's more that they weren't authorized, allegedly
Facebook parent Meta openly collects data from its billions of users, but when other companies scrape said data, it's a problem, according to a pair of lawsuits filed today.
Scraping involves extracting data from publicly available sources, as well as private data kept behind login pages, without user permission. Part of the risk from companies like Octopus, Romero wrote, is that they provide automated scraping services to anyone, regardless of who they may be targeting, or why.
According to Romero, users self-compromised their accounts when signing up for Octopus's service by handing login credentials over to the company. Octoparse was designed"to scrape data accessible to the user when logged into their accounts." Data scraped included email addresses, phone numbers, gender, birth date, post likes/comments, and more.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Meta claims breakthrough in 'superpower' AI translation as it interprets more than 200 languagesIt's the latest news from the controversial field of artificial intelligence, with hopes that it could revolutionise translation techniques.
Read more »
Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients - Virology JournalBackground We conducted a systematic review and meta-analysis to evaluate the efficacy of ivermectin for COVID-19 patients based on current peer-reviewed RCTs and to address disputes over the existing evidence. Methods MEDLINE (Pubmed), Scopus, Web of Science, Cochrane library, Google scholar and Clinicaltrials.gov were searched for RCTs assessing the efficacy of Ivermectin up to 20 February 2022. A systematic review and meta-analysis of studies was performed based on the PRISMA 2020 statement criteria. Results 19 and 17 studies were included in this systematic review and meta-analysis, respectively. There was no significant difference in progression to severe disease (log OR − 0.27 [95% CI − 0.61 to 0.08], I2 = 42.29%), negative RT-PCR (log OR 0.25 [95% CI − 0.18–0.68], I2 = 58.73%), recovery (log OR 0.11 [95% CI − 0.22–0.45], I2 = 13.84%), duration of hospitalization (SMD − 0.40 [95% CI − 0.85–0.06], I2 = 88.90%), time to negative RT-PCR (SMD − 0.36 [95% CI − 0.89–0.17], I2 = 46.2%), and viral load (SMD -0.17 [95% CI -0.45 to 0.12], I^2 = 0%). It is worth noting that, based on low-certainty evidence, ivermectin may possibly reduce mortality (log OR − 0.67 [95% CI − 1.20 to − 0.13], I2 = 28.96%). However, studies with a higher risk of bias were more likely to indicate positive effects on the efficacy of this drug, according to our subgroup analyses based on study quality. Conclusion Ivermectin did not have any significant effect on outcomes of COVID-19 patients and as WHO recommends, use of ivermectin should be limited to clinical trials.
Read more »
UK, South Korea, strike data-sharing pactTime to bone up on Hancom Office, the productivity suite that's big in Korea – and nowhere else
Read more »